Our Pricing

Mounjaro Dose Chart: Complete UK Dosing Schedule and Titration Guide

The mounjaro dose chart is essential for understanding the structured titration schedule that optimises weight loss outcomes whilst minimising side effects. Mounjaro (tirzepatide) follows a carefully designed dose escalation protocol starting at 2.5mg and increasing gradually to a maximum maintenance dose of 15mg, with each dose level maintained for at least four weeks. This evidence-based approach, validated in the SURPASS clinical trial programme, allows your body to adapt progressively to the medication whilst achieving clinically significant weight reduction.

Understanding the Mounjaro Dose Chart Titration Schedule

The mounjaro dose chart follows a five-step titration protocol designed to balance efficacy with tolerability. Treatment begins with a 2.5mg subcutaneous injection once weekly for four weeks, serving as an initiation dose that allows your body to adjust to tirzepatide's dual GIP and GLP-1 receptor agonist activity[1]. This starting dose is not considered therapeutic for weight loss but establishes baseline tolerance.

After the initial four-week period, the dose increases to 5mg weekly, representing the first therapeutic level where weight loss typically becomes evident. Clinical data from the SURMOUNT-1 trial demonstrated that patients at the 5mg dose achieved an average weight reduction of 15% over 72 weeks[2]. The mounjaro dose chart then progresses through 7.5mg, 10mg, 12.5mg, and finally 15mg, with each increment maintained for a minimum of four weeks before advancing.

Dose escalation decisions should always be made in consultation with your prescribing clinician, who will assess your response, tolerability, and weight loss trajectory. Some patients achieve their target weight at lower maintenance doses such as 7.5mg or 10mg and may not require progression to the maximum 15mg dose. The structured mounjaro dose chart ensures systematic monitoring at each titration point.

Why the Mounjaro Dose Chart Uses Four-Week Intervals

The four-week interval between dose increases in the mounjaro dose chart is pharmacologically justified by tirzepatide's mechanism of action and side effect profile. Gastrointestinal adverse events such as nausea, vomiting, and diarrhoea are most common during the first few weeks after dose escalation, typically peaking within 3-5 days and resolving within two weeks[1]. The four-week stabilisation period allows complete adaptation before introducing a higher dose.

This graduated approach also enables accurate assessment of weight loss response at each dose level. Tirzepatide's effects on appetite suppression, delayed gastric emptying, and metabolic parameters reach steady state approximately two weeks after dose initiation, with maximal weight reduction observable by week four. Clinicians use this data to determine whether further dose escalation is warranted or whether the current level represents an optimal maintenance dose for individual patients.

Mounjaro Dose Chart: Complete Dosing Table by Week

The complete mounjaro dose chart spans a minimum of 20 weeks from initiation to maximum dose, though many patients remain on intermediate doses as their maintenance level. Week 1-4: 2.5mg once weekly (initiation dose). Week 5-8: 5mg once weekly (first therapeutic dose). Week 9-12: 7.5mg once weekly (intermediate dose). Week 13-16: 10mg once weekly (standard maintenance for many patients). Week 17-20: 12.5mg once weekly (higher maintenance). Week 21 onwards: 15mg once weekly (maximum licensed dose)[3].

At Cured Pharmacy, Mounjaro is available from £124.99 following clinical assessment by our UK-registered prescribers, with transparent pricing across all dose strengths. Each KwikPen device delivers four weekly doses of the same strength, requiring a new pen when progressing to the next dose level in the mounjaro dose chart. Our clinical team provides ongoing monitoring throughout your titration schedule, ensuring safe progression and optimal outcomes.

The mounjaro dose chart is not rigid—your prescriber may hold a dose level for longer than four weeks if you experience persistent side effects or if weight loss continues satisfactorily at the current dose. Conversely, if tolerability is excellent and weight loss plateaus, earlier escalation may be considered. This individualised approach, guided by the structured mounjaro dose chart framework, optimises both safety and efficacy.

Clinical Evidence Supporting the Mounjaro Dose Chart Protocol

The mounjaro dose chart titration protocol is derived directly from the SURPASS and SURMOUNT clinical trial programmes, which enrolled over 10,000 participants across multiple studies. The SURMOUNT-1 trial, specifically designed to evaluate tirzepatide for weight management in adults without diabetes, demonstrated dose-dependent efficacy: 5mg achieved 15.0% mean weight reduction, 10mg achieved 19.5%, and 15mg achieved 20.9% at 72 weeks[2]. These results validated the dose escalation strategy embedded in the mounjaro dose chart.

The SURPASS-2 trial compared tirzepatide against semaglutide 1mg in patients with type 2 diabetes, showing superior weight loss across all tirzepatide dose levels following the standard mounjaro dose chart protocol[4]. At 40 weeks, the 15mg tirzepatide group achieved 11.2kg mean weight reduction compared to 5.7kg with semaglutide, demonstrating the clinical value of the higher dose tiers in the mounjaro dose chart.

Safety data from these trials informed the four-week titration intervals in the mounjaro dose chart. Gastrointestinal adverse events were predominantly mild to moderate and decreased in frequency with continued treatment, supporting the gradual dose escalation approach. Discontinuation rates due to adverse events remained below 7% across all dose groups, indicating the mounjaro dose chart protocol is well-tolerated when followed correctly[2].

Real-World Application of the Mounjaro Dose Chart in UK Practice

In UK clinical practice, adherence to the mounjaro dose chart protocol varies based on individual patient factors including baseline BMI, comorbidities, medication tolerability, and weight loss goals. Our experience at Cured Pharmacy shows that approximately 60% of patients progress to the 10mg or 12.5mg maintenance dose, whilst around 25% achieve satisfactory outcomes at 7.5mg and do not require further escalation. Only a minority require the maximum 15mg dose to reach their target weight.

The mounjaro dose chart also accommodates dose reduction if side effects become problematic at higher levels. Returning to the previous dose for an additional four weeks often resolves tolerability issues whilst maintaining therapeutic benefit. This flexibility within the structured mounjaro dose chart framework ensures personalised treatment whilst adhering to evidence-based protocols.

Mounjaro Dose Chart Compared to Other Weight Loss Injection Schedules

The mounjaro dose chart differs significantly from other GLP-1 receptor agonist titration protocols. Wegovy (semaglutide) uses a five-month escalation schedule: 0.25mg for four weeks, 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, then 2.4mg maintenance[5]. This longer titration period reflects semaglutide's different pharmacokinetic profile and side effect trajectory compared to the mounjaro dose chart.

Saxenda (liraglutide) requires daily injections with weekly dose increases: 0.6mg daily for week one, 1.2mg for week two, 1.8mg for week three, 2.4mg for week four, and 3.0mg maintenance from week five. This more rapid escalation in the Saxenda protocol contrasts with the mounjaro dose chart's four-week stabilisation periods, reflecting liraglutide's shorter half-life and daily dosing requirement.

The mounjaro dose chart's structured approach with consistent four-week intervals provides clearer monitoring points for both patients and prescribers. The once-weekly injection schedule also improves adherence compared to daily regimens, whilst the dose-dependent efficacy demonstrated in clinical trials gives clinicians confidence in escalating to higher doses when needed to achieve weight loss targets.

Following the Mounjaro Dose Chart: Practical Patient Guidance

Successful navigation of the mounjaro dose chart requires understanding injection technique, timing consistency, and side effect management. Administer your once-weekly dose on the same day each week, ideally at the same time, though the specific time is less critical than day consistency. Inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipohypertrophy[3].

When progressing to the next level in the mounjaro dose chart, you will receive a new KwikPen containing four doses of the higher strength. Do not attempt to adjust doses by injecting partial volumes—each pen is calibrated to deliver the precise dose indicated on the label. If you miss a dose and the next scheduled dose is more than four days away, take the missed dose as soon as possible. If fewer than four days remain, skip the missed dose and resume your normal schedule.

Side effect management is crucial for successful progression through the mounjaro dose chart. Nausea typically peaks 1-3 days after injection and improves by day 5-7. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can minimise gastrointestinal symptoms. If side effects are severe or persistent beyond two weeks at a new dose level, contact your prescriber before the next scheduled escalation in the mounjaro dose chart.

When to Hold or Reduce Doses in the Mounjaro Dose Chart

The mounjaro dose chart allows flexibility for dose holding or reduction based on individual response. If you experience persistent nausea, vomiting, or diarrhoea that interferes with daily activities or causes dehydration, maintain your current dose for an additional four weeks rather than escalating. If symptoms remain problematic, reducing to the previous dose level is appropriate and does not compromise long-term weight loss outcomes.

Conversely, if you achieve your target weight or reach a weight loss plateau that satisfies your clinical goals at an intermediate dose such as 7.5mg or 10mg, there is no requirement to escalate to the maximum 15mg dose. The mounjaro dose chart provides a framework, but your maintenance dose should be the lowest effective level that achieves and sustains your weight loss objectives whilst minimising side effects.

Accessing Mounjaro Through the Mounjaro Dose Chart Protocol at Cured Pharmacy

At Cured Pharmacy, we provide Mounjaro from £124.99 following a comprehensive online clinical assessment by our UK-registered prescribers. Our assessment evaluates your eligibility for Mounjaro based on BMI criteria (≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity), medical history, current medications, and contraindications. If approved, your prescription specifies the appropriate starting dose according to the mounjaro dose chart protocol.

Our clinical team provides ongoing support throughout your progression through the mounjaro dose chart, with regular check-ins at each dose escalation point to assess weight loss response, tolerability, and any emerging side effects. We coordinate with your NHS GP when appropriate and ensure continuity of care throughout your treatment journey. All Mounjaro supplied by Cured Pharmacy is UK-licensed, sourced from verified pharmaceutical distributors, and delivered in discreet packaging.

New patients can Save £20 on their first order using code Weightlossnew, making the initial 2.5mg dose particularly affordable whilst you assess tolerability. As you progress through the mounjaro dose chart to higher maintenance doses, our transparent pricing structure ensures you know the exact cost at each level with no hidden fees. Start your clinical assessment today to begin your evidence-based weight loss journey following the proven mounjaro dose chart protocol.

Mounjaro Dose Chart Monitoring and Follow-Up Schedule

Effective use of the mounjaro dose chart requires structured monitoring at defined intervals. We recommend clinical review at weeks 4, 8, 12, 16, and 20 as you progress through dose escalation, then every 12 weeks once you reach your maintenance dose. These reviews assess weight loss trajectory, side effect profile, adherence, and whether dose adjustment is warranted.

Laboratory monitoring may include baseline and periodic assessment of renal function, lipid profile, HbA1c (if diabetic or pre-diabetic), and liver function tests. The mounjaro dose chart protocol itself does not mandate specific laboratory intervals, but your prescriber will determine appropriate monitoring based on your individual risk factors and comorbidities. This comprehensive approach ensures safe, effective progression through the mounjaro dose chart whilst optimising long-term weight management outcomes.

Scientific References

1. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. UK Medicines and Healthcare products Regulatory Agency.
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
3. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE guideline.
4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.
5. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. UK Medicines and Healthcare products Regulatory Agency.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.